Generic competition · all medicines · read 12 November 2026

Is there a generic of Trametinib Dimethyl Sulfoxide, and who makes it?

Trametinib Dimethyl Sulfoxide appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came 11.2 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.

Trametinib Dimethyl Sulfoxide2 dosage-form groups in the Orange Book

0generic makers listed

Trametinib Dimethyl Sulfoxide appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
Where both are dated, the first generic approval came 11.2 years after the first brand approval.
Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Mekinist. No generic is listed as marketed (2 generic products listed as discontinued).

generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

16 March 2030Exclusivity ODE-428 Mekinist
16 September 2030Exclusivity PED Mekinist
29 May 2027Patent 7378423 drug substance
29 November 2027Patent 7378423*PED
15 October 2030Patent 8703781 drug substance
15 October 2030Patent 8952018
15 April 2031Patent 8952018*PED
15 April 2031Patent 8703781*PED
28 January 2032Patent 8580304 drug product
28 January 2032Patent 9399021 drug product

8 more patents are listed.

Solution, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Mekinist. No generic is listed as marketed.

generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

16 March 2030Exclusivity ODE-428 Mekinist
16 September 2030Exclusivity PED Mekinist
29 May 2027Patent 7378423 drug substance
29 November 2027Patent 7378423*PED
15 October 2030Patent 8703781 drug substance
15 April 2031Patent 8703781*PED

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.